Egbaria Kamel 4
4 · HI TECH PHARMACAL CO INC · Filed Jul 18, 2012
Insider Transaction Report
Form 4
Egbaria Kamel
Chief Scientific Officer, EVP
Transactions
- Exercise/Conversion
Common Stock
2012-07-17$23.10/sh+11,342$262,000→ 11,342 total - Sale
Common Stock
2012-07-17$32.56/sh−11,342$369,296→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2012-07-17−11,342→ 28,658 totalExercise: $23.10From: 2011-04-26Exp: 2020-04-26→ Common Stock (11,342 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.46 to 32.71, inclusive. The reporting person undertakes to provide Hi-Tech Pharmacal Co., Inc., any security holder of Hi-Tech Pharmacal Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) of this Form 4.
- [F2]Stock Option granted under Hi-Tech Pharmacal Co., Inc.'s 2009 Stock Option Plan, which is a Rule 16b-3 Plan.
- [F3]The option becomes exercisable in four (4) equal annual installments beginning on the first anniversary of the grant date.
- [F4]Other than the option to acquire 28,658 shares reflected on this form as still held by the filer following the reported transactions, the filer is also the holder of additional options to acquire 80,000 shares of Hi-Tech common stock (for a total of 108,658 options still held by the filer), which options were granted on various dates, with various exercise prices, exercise dates, and expiration dates.